Celgene investors’ CVR payment looks rocky, as FDA rejects i...

The chances of former shareholders in Celgene missing out on the big pay-out from their contingent value right (CVR) deal with Bristol-Myers Squibb have risen sharply, aft

Study sets benchmark for cost of repurposed coronavirus drug...

Scientists have warned that the main drugs being repurposed for COVID-19 could end up being too expensive for many people around the world – unless drugmakers are prepared to s

CHMP backs BMS’ first-in-class anaemia drug Reblozyl

J&J defends Darzalex with FDA approval for faster dosing

Novartis on point in EU for asthma triple as CHMP backs Ener...